Results

1–10 of 18 results for aflibercept 8 mg

Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2025
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Annual Meeting Talks
2025
Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals at Week 96 in nAMD: A PULSAR Post Hoc Analysis
Michael W. Stewart, MD
Annual Meeting Talks
2025
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Annual Meeting Talks
2025
Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema SwitchingFrom Other Anti-VEGF Agents
Michael Javaheri, MD
Annual Meeting Talks
2025
Pooled Safety Analysis of Aflibercept 8 mg in the CANDELA PHOTON and PULSAR Trials
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2023
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023
Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration
Keyvan Koushan, MD, FRCSC
Annual Meeting Talks
2023